114P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study Article Swipe
Christian Jackisch
,
S-A. Im
,
André Mattar
,
Rámón Colomer
,
Daniil Stroyakovskiy
,
Zbigniew Nowecki
,
Michelino De Laurentiis
,
J-Y Pierga
,
Kyung Hae Jung
,
Christian Schem
,
Sarah Heeson
,
Veronica Craine
,
Bing Wang
,
Eleonora Restuccia
,
Antoinette R. Tan
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.esmoop.2024.103102
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.esmoop.2024.103102
The primary analysis of the FeDeriCa study (NCT03493854; Tan AR, et al. Lancet Oncol 2021) showed that PH FDC SC cycle 7 P and H serum trough concentrations were non-inferior to intravenous (IV) P and H, with comparable total pathological complete response rates and safety profiles when given as neoadjuvant therapy for HER2-positive EBC. Here we report long-term efficacy and safety data. Patients (pts) had HER2-positive operable, locally advanced or inflammatory stage II–IIIC BC and left ventricular ejection fraction ≥55%. They received eight cycles of neoadjuvant chemotherapy (one of two standard regimens chosen by the investigator) + P IV (840 mg loading dose then 420 mg maintenance) + H IV (8 mg/kg then 6 mg/kg) or PH FDC SC (1200 mg P/600 mg H then 600 mg each as FDC SC) every 3 weeks during cycles 5–8 in a 1:1 randomisation design. Pts continued adjuvant HER2-targeted treatment after surgery, per randomisation, to complete 18 cycles. Secondary endpoints included invasive disease-free survival (iDFS), event-free survival (EFS), distant recurrence-free interval (DRFI), overall survival (OS) and safety (focusing on cardiac adverse events). Data cut-off was 2 Jun, 2023; median follow-up was 51.4 months in the P + H IV arm and 51.2 months in the PH FDC SC arm. Long-term efficacy data are shown in the table. No new safety signals, including for cardiac safety, were observed.Table: 114PP + H IV n = 252PH FDC SC n = 248iDFSPts who underwent surgery, n239234Pts with event, n (%)23 (9.6)26 (11.1)Unstratified hazard ratio (HR)(95% confidence interval [CI])1.13 (0.64, 1.97)4-year event-free rate (95% CI)89.5 (85.4, 93.6)88.5 (84.3, 92.7)EFSPts, n252248Pts with event, n (%)29 (11.5)32 (12.9)HR (95% CI)1.20 (0.72, 1.98)4-year event-free rate (95% CI)88.5 (84.4, 92.5)86.6 (82.2, 90.9)DRFIPts, n252248Pts with event, n (%)18 (7.1)19 (7.7)HR (95% CI)1.17 (0.61, 2.24)4-year event-free rate (95% CI)92.5 (89.2, 95.8)91.9 (88.4, 95.4)OSPts, n252248Pts with event, n %12 (4.8)14 (5.6)HR (95% CI)1.26 (0.58, 2.72)4-year event-free rate (95% CI)95.5 (92.9, 98.1)94.1 (91.1, 97.1) Open table in a new tab The long-term efficacy of PH FDC SC was comparable to that of P + H IV. Safety remained similar to P + H IV and consistent with P + H + chemotherapy. Overall, these findings support the primary analysis results. PH FDC SC is established as a faster, more convenient, less invasive, pt- and healthcare professional-preferred alternative to P + H IV for pts with HER2-positive BC.
Related Topics
Concepts
Pertuzumab
Trastuzumab
Medicine
Oncology
Chemotherapy
Fixed-dose combination
Breast cancer
Pharmacology
Internal medicine
Cancer
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.esmoop.2024.103102
- http://www.esmoopen.com/article/S2059702924008706/pdf
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4397007666
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4397007666Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.esmoop.2024.103102Digital Object Identifier
- Title
-
114P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa studyWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-05-01Full publication date if available
- Authors
-
Christian Jackisch, S-A. Im, André Mattar, Rámón Colomer, Daniil Stroyakovskiy, Zbigniew Nowecki, Michelino De Laurentiis, J-Y Pierga, Kyung Hae Jung, Christian Schem, Sarah Heeson, Veronica Craine, Bing Wang, Eleonora Restuccia, Antoinette R. TanList of authors in order
- Landing page
-
https://doi.org/10.1016/j.esmoop.2024.103102Publisher landing page
- PDF URL
-
https://www.esmoopen.com/article/S2059702924008706/pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.esmoopen.com/article/S2059702924008706/pdfDirect OA link when available
- Concepts
-
Pertuzumab, Trastuzumab, Medicine, Oncology, Chemotherapy, Fixed-dose combination, Breast cancer, Pharmacology, Internal medicine, CancerTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4397007666 |
|---|---|
| doi | https://doi.org/10.1016/j.esmoop.2024.103102 |
| ids.doi | https://doi.org/10.1016/j.esmoop.2024.103102 |
| ids.openalex | https://openalex.org/W4397007666 |
| fwci | 0.0 |
| type | article |
| title | 114P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study |
| biblio.issue | |
| biblio.volume | 9 |
| biblio.last_page | 103102 |
| biblio.first_page | 103102 |
| topics[0].id | https://openalex.org/T10183 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.9664000272750854 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1306 |
| topics[0].subfield.display_name | Cancer Research |
| topics[0].display_name | Breast Cancer Treatment Studies |
| topics[1].id | https://openalex.org/T10755 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9347000122070312 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | HER2/EGFR in Cancer Research |
| topics[2].id | https://openalex.org/T12829 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9212999939918518 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2740 |
| topics[2].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[2].display_name | Advanced Breast Cancer Therapies |
| is_xpac | False |
| apc_list.value | 2750 |
| apc_list.currency | EUR |
| apc_list.value_usd | 2965 |
| apc_paid.value | 2750 |
| apc_paid.currency | EUR |
| apc_paid.value_usd | 2965 |
| concepts[0].id | https://openalex.org/C2781164504 |
| concepts[0].level | 5 |
| concepts[0].score | 0.9791195392608643 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1998021 |
| concepts[0].display_name | Pertuzumab |
| concepts[1].id | https://openalex.org/C2779786085 |
| concepts[1].level | 4 |
| concepts[1].score | 0.8599064350128174 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q412616 |
| concepts[1].display_name | Trastuzumab |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.7406769394874573 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C143998085 |
| concepts[3].level | 1 |
| concepts[3].score | 0.5755435228347778 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[3].display_name | Oncology |
| concepts[4].id | https://openalex.org/C2776694085 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5307300686836243 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[4].display_name | Chemotherapy |
| concepts[5].id | https://openalex.org/C2776623344 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5077584981918335 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q5456317 |
| concepts[5].display_name | Fixed-dose combination |
| concepts[6].id | https://openalex.org/C530470458 |
| concepts[6].level | 3 |
| concepts[6].score | 0.474829763174057 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q128581 |
| concepts[6].display_name | Breast cancer |
| concepts[7].id | https://openalex.org/C98274493 |
| concepts[7].level | 1 |
| concepts[7].score | 0.4315984547138214 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[7].display_name | Pharmacology |
| concepts[8].id | https://openalex.org/C126322002 |
| concepts[8].level | 1 |
| concepts[8].score | 0.4301174283027649 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[8].display_name | Internal medicine |
| concepts[9].id | https://openalex.org/C121608353 |
| concepts[9].level | 2 |
| concepts[9].score | 0.27269381284713745 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[9].display_name | Cancer |
| keywords[0].id | https://openalex.org/keywords/pertuzumab |
| keywords[0].score | 0.9791195392608643 |
| keywords[0].display_name | Pertuzumab |
| keywords[1].id | https://openalex.org/keywords/trastuzumab |
| keywords[1].score | 0.8599064350128174 |
| keywords[1].display_name | Trastuzumab |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.7406769394874573 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/oncology |
| keywords[3].score | 0.5755435228347778 |
| keywords[3].display_name | Oncology |
| keywords[4].id | https://openalex.org/keywords/chemotherapy |
| keywords[4].score | 0.5307300686836243 |
| keywords[4].display_name | Chemotherapy |
| keywords[5].id | https://openalex.org/keywords/fixed-dose-combination |
| keywords[5].score | 0.5077584981918335 |
| keywords[5].display_name | Fixed-dose combination |
| keywords[6].id | https://openalex.org/keywords/breast-cancer |
| keywords[6].score | 0.474829763174057 |
| keywords[6].display_name | Breast cancer |
| keywords[7].id | https://openalex.org/keywords/pharmacology |
| keywords[7].score | 0.4315984547138214 |
| keywords[7].display_name | Pharmacology |
| keywords[8].id | https://openalex.org/keywords/internal-medicine |
| keywords[8].score | 0.4301174283027649 |
| keywords[8].display_name | Internal medicine |
| keywords[9].id | https://openalex.org/keywords/cancer |
| keywords[9].score | 0.27269381284713745 |
| keywords[9].display_name | Cancer |
| language | en |
| locations[0].id | doi:10.1016/j.esmoop.2024.103102 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210217024 |
| locations[0].source.issn | 2059-7029 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2059-7029 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | ESMO Open |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | http://www.esmoopen.com/article/S2059702924008706/pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | ESMO Open |
| locations[0].landing_page_url | https://doi.org/10.1016/j.esmoop.2024.103102 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5016987068 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-8537-3743 |
| authorships[0].author.display_name | Christian Jackisch |
| authorships[0].countries | DE |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210140647 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Obstetrics and Gynecology, Sana Klinikum Offenbach, Offenbach, Germany |
| authorships[0].institutions[0].id | https://openalex.org/I4210140647 |
| authorships[0].institutions[0].ror | https://ror.org/04k4vsv28 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210140647 |
| authorships[0].institutions[0].country_code | DE |
| authorships[0].institutions[0].display_name | Sana Klinikum Offenbach |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | C. Jackisch |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Obstetrics and Gynecology, Sana Klinikum Offenbach, Offenbach, Germany |
| authorships[1].author.id | https://openalex.org/A5101053379 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | S-A. Im |
| authorships[1].countries | KR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I2802835388 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea |
| authorships[1].institutions[0].id | https://openalex.org/I2802835388 |
| authorships[1].institutions[0].ror | https://ror.org/01z4nnt86 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I2802835388 |
| authorships[1].institutions[0].country_code | KR |
| authorships[1].institutions[0].display_name | Seoul National University Hospital |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | S-A. Im |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea |
| authorships[2].author.id | https://openalex.org/A5028812536 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-5973-623X |
| authorships[2].author.display_name | André Mattar |
| authorships[2].countries | BR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210143548 |
| authorships[2].affiliations[0].raw_affiliation_string | CRSM, Hospital Pérola Byington, São Paulo, Brazil |
| authorships[2].institutions[0].id | https://openalex.org/I4210143548 |
| authorships[2].institutions[0].ror | https://ror.org/0495f8j82 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210143548 |
| authorships[2].institutions[0].country_code | BR |
| authorships[2].institutions[0].display_name | Hospital da Mulher São Paulo |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | A. Mattar |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | CRSM, Hospital Pérola Byington, São Paulo, Brazil |
| authorships[3].author.id | https://openalex.org/A5047280933 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-6393-3444 |
| authorships[3].author.display_name | Rámón Colomer |
| authorships[3].countries | ES |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210130498 |
| authorships[3].affiliations[0].raw_affiliation_string | Division of Medical Oncology, Hospital Universitario La Princesa, Madrid, Spain |
| authorships[3].institutions[0].id | https://openalex.org/I4210130498 |
| authorships[3].institutions[0].ror | https://ror.org/03cg5md32 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210130498, https://openalex.org/I4210139293 |
| authorships[3].institutions[0].country_code | ES |
| authorships[3].institutions[0].display_name | Hospital Universitario de La Princesa |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | R. Colomer Bosch |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Division of Medical Oncology, Hospital Universitario La Princesa, Madrid, Spain |
| authorships[4].author.id | https://openalex.org/A5071263994 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-1973-1092 |
| authorships[4].author.display_name | Daniil Stroyakovskiy |
| authorships[4].countries | RU |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210167281 |
| authorships[4].affiliations[0].raw_affiliation_string | Moscow Healthcare Department, City Clinical Oncology Hospital 62, Moscow, Russian Federation |
| authorships[4].institutions[0].id | https://openalex.org/I4210167281 |
| authorships[4].institutions[0].ror | https://ror.org/05qy4jt44 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210167281 |
| authorships[4].institutions[0].country_code | RU |
| authorships[4].institutions[0].display_name | Moscow City Oncology Hospital №62 |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | D. Stroyakovskiy |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Moscow Healthcare Department, City Clinical Oncology Hospital 62, Moscow, Russian Federation |
| authorships[5].author.id | https://openalex.org/A5059490423 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-7706-8191 |
| authorships[5].author.display_name | Zbigniew Nowecki |
| authorships[5].countries | PL |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210150880 |
| authorships[5].affiliations[0].raw_affiliation_string | Breast Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland |
| authorships[5].institutions[0].id | https://openalex.org/I4210150880 |
| authorships[5].institutions[0].ror | https://ror.org/04qcjsm24 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210150880 |
| authorships[5].institutions[0].country_code | PL |
| authorships[5].institutions[0].display_name | The Maria Sklodowska-Curie National Research Institute of Oncology |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Z. Nowecki |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Breast Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland |
| authorships[6].author.id | https://openalex.org/A5025684262 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-9009-1572 |
| authorships[6].author.display_name | Michelino De Laurentiis |
| authorships[6].countries | IT |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210141868 |
| authorships[6].affiliations[0].raw_affiliation_string | Breast Department, Istituto Nazionale Tumori IRCCS 'Fondazione Pascale', Naples, Italy |
| authorships[6].institutions[0].id | https://openalex.org/I4210141868 |
| authorships[6].institutions[0].ror | https://ror.org/0506y2b23 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210141868, https://openalex.org/I4210153126 |
| authorships[6].institutions[0].country_code | IT |
| authorships[6].institutions[0].display_name | Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | M. De Laurentiis |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Breast Department, Istituto Nazionale Tumori IRCCS 'Fondazione Pascale', Naples, Italy |
| authorships[7].author.id | https://openalex.org/A5055143063 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | J-Y Pierga |
| authorships[7].countries | FR |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I204730241, https://openalex.org/I80043 |
| authorships[7].affiliations[0].raw_affiliation_string | Institut Curie, Université de Paris, Paris, France |
| authorships[7].institutions[0].id | https://openalex.org/I80043 |
| authorships[7].institutions[0].ror | https://ror.org/04t0gwh46 |
| authorships[7].institutions[0].type | nonprofit |
| authorships[7].institutions[0].lineage | https://openalex.org/I80043 |
| authorships[7].institutions[0].country_code | FR |
| authorships[7].institutions[0].display_name | Institut Curie |
| authorships[7].institutions[1].id | https://openalex.org/I204730241 |
| authorships[7].institutions[1].ror | https://ror.org/05f82e368 |
| authorships[7].institutions[1].type | education |
| authorships[7].institutions[1].lineage | https://openalex.org/I204730241 |
| authorships[7].institutions[1].country_code | FR |
| authorships[7].institutions[1].display_name | Université Paris Cité |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | J-Y. Pierga |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Institut Curie, Université de Paris, Paris, France |
| authorships[8].author.id | https://openalex.org/A5049348377 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-1580-7224 |
| authorships[8].author.display_name | Kyung Hae Jung |
| authorships[8].countries | KR |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I116631150, https://openalex.org/I2801680663, https://openalex.org/I40542001 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea |
| authorships[8].institutions[0].id | https://openalex.org/I2801680663 |
| authorships[8].institutions[0].ror | https://ror.org/03s5q0090 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I2801680663, https://openalex.org/I4210167194 |
| authorships[8].institutions[0].country_code | KR |
| authorships[8].institutions[0].display_name | Asan Medical Center |
| authorships[8].institutions[1].id | https://openalex.org/I116631150 |
| authorships[8].institutions[1].ror | https://ror.org/02tec3785 |
| authorships[8].institutions[1].type | education |
| authorships[8].institutions[1].lineage | https://openalex.org/I116631150 |
| authorships[8].institutions[1].country_code | KR |
| authorships[8].institutions[1].display_name | Ulsan College |
| authorships[8].institutions[2].id | https://openalex.org/I40542001 |
| authorships[8].institutions[2].ror | https://ror.org/02c2f8975 |
| authorships[8].institutions[2].type | education |
| authorships[8].institutions[2].lineage | https://openalex.org/I40542001 |
| authorships[8].institutions[2].country_code | KR |
| authorships[8].institutions[2].display_name | University of Ulsan |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | K.H. Jung |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea |
| authorships[9].author.id | https://openalex.org/A5032626301 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-8606-3077 |
| authorships[9].author.display_name | Christian Schem |
| authorships[9].countries | DE |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210125971, https://openalex.org/I4210163264 |
| authorships[9].affiliations[0].raw_affiliation_string | Krankenhaus Jerusalem, Mammazentrum Hamburg, Hamburg, Germany |
| authorships[9].institutions[0].id | https://openalex.org/I4210163264 |
| authorships[9].institutions[0].ror | https://ror.org/05yh2yz22 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210163264 |
| authorships[9].institutions[0].country_code | DE |
| authorships[9].institutions[0].display_name | Krankenhaus Jerusalem |
| authorships[9].institutions[1].id | https://openalex.org/I4210125971 |
| authorships[9].institutions[1].ror | https://ror.org/02nyezm25 |
| authorships[9].institutions[1].type | healthcare |
| authorships[9].institutions[1].lineage | https://openalex.org/I4210125971 |
| authorships[9].institutions[1].country_code | DE |
| authorships[9].institutions[1].display_name | Mammazentrum Hamburg |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | C. Schem |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Krankenhaus Jerusalem, Mammazentrum Hamburg, Hamburg, Germany |
| authorships[10].author.id | https://openalex.org/A5069502587 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Sarah Heeson |
| authorships[10].countries | GB |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210113058 |
| authorships[10].affiliations[0].raw_affiliation_string | PDO–Clinical Science Oncology, Roche Products Limited, Welwyn Garden City, UK |
| authorships[10].institutions[0].id | https://openalex.org/I4210113058 |
| authorships[10].institutions[0].ror | https://ror.org/024tgbv41 |
| authorships[10].institutions[0].type | company |
| authorships[10].institutions[0].lineage | https://openalex.org/I118019719, https://openalex.org/I4210113058 |
| authorships[10].institutions[0].country_code | GB |
| authorships[10].institutions[0].display_name | Roche (United Kingdom) |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | S.H. Heeson |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | PDO–Clinical Science Oncology, Roche Products Limited, Welwyn Garden City, UK |
| authorships[11].author.id | https://openalex.org/A5012158679 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Veronica Craine |
| authorships[11].countries | CA |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210089084 |
| authorships[11].affiliations[0].raw_affiliation_string | Biostatistics, Hoffmann-La Roche Ltd., Mississauga, ON, Canada |
| authorships[11].institutions[0].id | https://openalex.org/I4210089084 |
| authorships[11].institutions[0].ror | https://ror.org/006hrz834 |
| authorships[11].institutions[0].type | company |
| authorships[11].institutions[0].lineage | https://openalex.org/I118019719, https://openalex.org/I4210089084 |
| authorships[11].institutions[0].country_code | CA |
| authorships[11].institutions[0].display_name | Roche (Canada) |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | V. Craine |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Biostatistics, Hoffmann-La Roche Ltd., Mississauga, ON, Canada |
| authorships[12].author.id | https://openalex.org/A5100382571 |
| authorships[12].author.orcid | https://orcid.org/0009-0004-0974-1830 |
| authorships[12].author.display_name | Bing Wang |
| authorships[12].affiliations[0].raw_affiliation_string | Clinical Pharmacology, Genentech Research and Early Development, Genentech, Inc., South San Francisco, CA, USA |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | B. Wang |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Clinical Pharmacology, Genentech Research and Early Development, Genentech, Inc., South San Francisco, CA, USA |
| authorships[13].author.id | https://openalex.org/A5068222768 |
| authorships[13].author.orcid | https://orcid.org/0000-0001-5751-094X |
| authorships[13].author.display_name | Eleonora Restuccia |
| authorships[13].countries | CH |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I118019719 |
| authorships[13].affiliations[0].raw_affiliation_string | Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland |
| authorships[13].institutions[0].id | https://openalex.org/I118019719 |
| authorships[13].institutions[0].ror | https://ror.org/00by1q217 |
| authorships[13].institutions[0].type | company |
| authorships[13].institutions[0].lineage | https://openalex.org/I118019719 |
| authorships[13].institutions[0].country_code | CH |
| authorships[13].institutions[0].display_name | Roche (Switzerland) |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | E. Restuccia |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland |
| authorships[14].author.id | https://openalex.org/A5022891785 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-7895-7000 |
| authorships[14].author.display_name | Antoinette R. Tan |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210100342 |
| authorships[14].affiliations[0].raw_affiliation_string | Solid Tumor and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA |
| authorships[14].institutions[0].id | https://openalex.org/I4210100342 |
| authorships[14].institutions[0].ror | https://ror.org/0174nh398 |
| authorships[14].institutions[0].type | healthcare |
| authorships[14].institutions[0].lineage | https://openalex.org/I1334069289, https://openalex.org/I4210100342 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | Levine Cancer Institute |
| authorships[14].author_position | last |
| authorships[14].raw_author_name | A.R. Tan |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Solid Tumor and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | http://www.esmoopen.com/article/S2059702924008706/pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | 114P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10183 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.9664000272750854 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1306 |
| primary_topic.subfield.display_name | Cancer Research |
| primary_topic.display_name | Breast Cancer Treatment Studies |
| related_works | https://openalex.org/W3139229505, https://openalex.org/W3001641205, https://openalex.org/W2330582602, https://openalex.org/W2769397950, https://openalex.org/W4361939549, https://openalex.org/W2891579961, https://openalex.org/W3165774504, https://openalex.org/W2921099093, https://openalex.org/W2901986589, https://openalex.org/W2019769353 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1016/j.esmoop.2024.103102 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210217024 |
| best_oa_location.source.issn | 2059-7029 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2059-7029 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | ESMO Open |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | http://www.esmoopen.com/article/S2059702924008706/pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | ESMO Open |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.esmoop.2024.103102 |
| primary_location.id | doi:10.1016/j.esmoop.2024.103102 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210217024 |
| primary_location.source.issn | 2059-7029 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2059-7029 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | ESMO Open |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | http://www.esmoopen.com/article/S2059702924008706/pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | ESMO Open |
| primary_location.landing_page_url | https://doi.org/10.1016/j.esmoop.2024.103102 |
| publication_date | 2024-05-01 |
| publication_year | 2024 |
| referenced_works_count | 0 |
| abstract_inverted_index.+ | 96, 107, 193, 225, 338, 346, 353, 355, 384 |
| abstract_inverted_index.2 | 182 |
| abstract_inverted_index.3 | 132 |
| abstract_inverted_index.6 | 113 |
| abstract_inverted_index.7 | 21 |
| abstract_inverted_index.= | 229, 234 |
| abstract_inverted_index.H | 24, 108, 123, 194, 226, 339, 347, 354, 385 |
| abstract_inverted_index.P | 22, 33, 97, 192, 337, 345, 352, 383 |
| abstract_inverted_index.a | 138, 322, 371 |
| abstract_inverted_index.n | 228, 233, 242, 265, 284, 303 |
| abstract_inverted_index.(8 | 110 |
| abstract_inverted_index.18 | 153 |
| abstract_inverted_index.BC | 73 |
| abstract_inverted_index.H, | 35 |
| abstract_inverted_index.IV | 98, 109, 195, 227, 348, 386 |
| abstract_inverted_index.No | 214 |
| abstract_inverted_index.PH | 17, 116, 202, 329, 365 |
| abstract_inverted_index.SC | 19, 118, 204, 232, 331, 367 |
| abstract_inverted_index.as | 48, 128, 370 |
| abstract_inverted_index.by | 93 |
| abstract_inverted_index.et | 10 |
| abstract_inverted_index.in | 137, 190, 200, 211, 321 |
| abstract_inverted_index.is | 368 |
| abstract_inverted_index.mg | 100, 105, 120, 122, 126 |
| abstract_inverted_index.of | 3, 84, 88, 328, 336 |
| abstract_inverted_index.on | 175 |
| abstract_inverted_index.or | 69, 115 |
| abstract_inverted_index.to | 30, 151, 334, 344, 382 |
| abstract_inverted_index.we | 55 |
| abstract_inverted_index.%12 | 304 |
| abstract_inverted_index.1:1 | 139 |
| abstract_inverted_index.420 | 104 |
| abstract_inverted_index.600 | 125 |
| abstract_inverted_index.AR, | 9 |
| abstract_inverted_index.BC. | 391 |
| abstract_inverted_index.FDC | 18, 117, 129, 203, 231, 330, 366 |
| abstract_inverted_index.IV. | 340 |
| abstract_inverted_index.Pts | 142 |
| abstract_inverted_index.SC) | 130 |
| abstract_inverted_index.Tan | 8 |
| abstract_inverted_index.The | 0, 325 |
| abstract_inverted_index.al. | 11 |
| abstract_inverted_index.and | 23, 34, 43, 59, 74, 172, 197, 349, 378 |
| abstract_inverted_index.are | 209 |
| abstract_inverted_index.arm | 196 |
| abstract_inverted_index.for | 51, 219, 387 |
| abstract_inverted_index.had | 64 |
| abstract_inverted_index.new | 215, 323 |
| abstract_inverted_index.per | 149 |
| abstract_inverted_index.pt- | 377 |
| abstract_inverted_index.pts | 388 |
| abstract_inverted_index.tab | 324 |
| abstract_inverted_index.the | 4, 94, 191, 201, 212, 361 |
| abstract_inverted_index.two | 89 |
| abstract_inverted_index.was | 181, 187, 332 |
| abstract_inverted_index.who | 236 |
| abstract_inverted_index.(840 | 99 |
| abstract_inverted_index.(95% | 256, 269, 275, 288, 294, 307, 313 |
| abstract_inverted_index.(IV) | 32 |
| abstract_inverted_index.(OS) | 171 |
| abstract_inverted_index.(one | 87 |
| abstract_inverted_index.51.2 | 198 |
| abstract_inverted_index.51.4 | 188 |
| abstract_inverted_index.Data | 179 |
| abstract_inverted_index.EBC. | 53 |
| abstract_inverted_index.Here | 54 |
| abstract_inverted_index.Jun, | 183 |
| abstract_inverted_index.Open | 319 |
| abstract_inverted_index.They | 80 |
| abstract_inverted_index.arm. | 205 |
| abstract_inverted_index.data | 208 |
| abstract_inverted_index.dose | 102 |
| abstract_inverted_index.each | 127 |
| abstract_inverted_index.left | 75 |
| abstract_inverted_index.less | 375 |
| abstract_inverted_index.more | 373 |
| abstract_inverted_index.rate | 255, 274, 293, 312 |
| abstract_inverted_index.that | 16, 335 |
| abstract_inverted_index.then | 103, 112, 124 |
| abstract_inverted_index.were | 28, 222 |
| abstract_inverted_index.when | 46 |
| abstract_inverted_index.with | 36, 240, 263, 282, 301, 351, 389 |
| abstract_inverted_index.(%)18 | 285 |
| abstract_inverted_index.(%)23 | 243 |
| abstract_inverted_index.(%)29 | 266 |
| abstract_inverted_index.(1200 | 119 |
| abstract_inverted_index.(pts) | 63 |
| abstract_inverted_index.114PP | 224 |
| abstract_inverted_index.2021) | 14 |
| abstract_inverted_index.2023; | 184 |
| abstract_inverted_index.252PH | 230 |
| abstract_inverted_index.5–8 | 136 |
| abstract_inverted_index.97.1) | 318 |
| abstract_inverted_index.Oncol | 13 |
| abstract_inverted_index.P/600 | 121 |
| abstract_inverted_index.after | 147 |
| abstract_inverted_index.cycle | 20 |
| abstract_inverted_index.data. | 61 |
| abstract_inverted_index.eight | 82 |
| abstract_inverted_index.every | 131 |
| abstract_inverted_index.given | 47 |
| abstract_inverted_index.mg/kg | 111 |
| abstract_inverted_index.rates | 42 |
| abstract_inverted_index.ratio | 247 |
| abstract_inverted_index.serum | 25 |
| abstract_inverted_index.shown | 210 |
| abstract_inverted_index.stage | 71 |
| abstract_inverted_index.study | 6 |
| abstract_inverted_index.table | 320 |
| abstract_inverted_index.these | 358 |
| abstract_inverted_index.total | 38 |
| abstract_inverted_index.weeks | 133 |
| abstract_inverted_index.(0.58, | 309 |
| abstract_inverted_index.(0.61, | 290 |
| abstract_inverted_index.(0.64, | 252 |
| abstract_inverted_index.(0.72, | 271 |
| abstract_inverted_index.(82.2, | 279 |
| abstract_inverted_index.(84.3, | 260 |
| abstract_inverted_index.(84.4, | 277 |
| abstract_inverted_index.(85.4, | 258 |
| abstract_inverted_index.(88.4, | 298 |
| abstract_inverted_index.(89.2, | 296 |
| abstract_inverted_index.(91.1, | 317 |
| abstract_inverted_index.(92.9, | 315 |
| abstract_inverted_index.(EFS), | 164 |
| abstract_inverted_index.Lancet | 12 |
| abstract_inverted_index.Safety | 341 |
| abstract_inverted_index.chosen | 92 |
| abstract_inverted_index.cycles | 83, 135 |
| abstract_inverted_index.during | 134 |
| abstract_inverted_index.event, | 241, 264, 283, 302 |
| abstract_inverted_index.hazard | 246 |
| abstract_inverted_index.median | 185 |
| abstract_inverted_index.mg/kg) | 114 |
| abstract_inverted_index.months | 189, 199 |
| abstract_inverted_index.report | 56 |
| abstract_inverted_index.safety | 44, 60, 173, 216 |
| abstract_inverted_index.showed | 15 |
| abstract_inverted_index.table. | 213 |
| abstract_inverted_index.trough | 26 |
| abstract_inverted_index.(4.8)14 | 305 |
| abstract_inverted_index.(5.6)HR | 306 |
| abstract_inverted_index.(7.1)19 | 286 |
| abstract_inverted_index.(7.7)HR | 287 |
| abstract_inverted_index.(9.6)26 | 244 |
| abstract_inverted_index.(DRFI), | 168 |
| abstract_inverted_index.(iDFS), | 161 |
| abstract_inverted_index.CI)1.17 | 289 |
| abstract_inverted_index.CI)1.20 | 270 |
| abstract_inverted_index.CI)1.26 | 308 |
| abstract_inverted_index.CI)88.5 | 276 |
| abstract_inverted_index.CI)89.5 | 257 |
| abstract_inverted_index.CI)92.5 | 295 |
| abstract_inverted_index.CI)95.5 | 314 |
| abstract_inverted_index.adverse | 177 |
| abstract_inverted_index.cardiac | 176, 220 |
| abstract_inverted_index.cut-off | 180 |
| abstract_inverted_index.cycles. | 154 |
| abstract_inverted_index.design. | 141 |
| abstract_inverted_index.distant | 165 |
| abstract_inverted_index.faster, | 372 |
| abstract_inverted_index.loading | 101 |
| abstract_inverted_index.locally | 67 |
| abstract_inverted_index.overall | 169 |
| abstract_inverted_index.primary | 1, 362 |
| abstract_inverted_index.safety, | 221 |
| abstract_inverted_index.similar | 343 |
| abstract_inverted_index.support | 360 |
| abstract_inverted_index.therapy | 50 |
| abstract_inverted_index.≥55%. | 79 |
| abstract_inverted_index.(11.5)32 | 267 |
| abstract_inverted_index.(12.9)HR | 268 |
| abstract_inverted_index.(HR)(95% | 248 |
| abstract_inverted_index.FeDeriCa | 5 |
| abstract_inverted_index.Overall, | 357 |
| abstract_inverted_index.Patients | 62 |
| abstract_inverted_index.adjuvant | 144 |
| abstract_inverted_index.advanced | 68 |
| abstract_inverted_index.analysis | 2, 363 |
| abstract_inverted_index.complete | 40, 152 |
| abstract_inverted_index.efficacy | 58, 207, 327 |
| abstract_inverted_index.ejection | 77 |
| abstract_inverted_index.events). | 178 |
| abstract_inverted_index.findings | 359 |
| abstract_inverted_index.fraction | 78 |
| abstract_inverted_index.included | 157 |
| abstract_inverted_index.interval | 167, 250 |
| abstract_inverted_index.invasive | 158 |
| abstract_inverted_index.profiles | 45 |
| abstract_inverted_index.received | 81 |
| abstract_inverted_index.regimens | 91 |
| abstract_inverted_index.remained | 342 |
| abstract_inverted_index.response | 41 |
| abstract_inverted_index.results. | 364 |
| abstract_inverted_index.signals, | 217 |
| abstract_inverted_index.standard | 90 |
| abstract_inverted_index.surgery, | 148, 238 |
| abstract_inverted_index.survival | 160, 163, 170 |
| abstract_inverted_index.(focusing | 174 |
| abstract_inverted_index.92.5)86.6 | 278 |
| abstract_inverted_index.93.6)88.5 | 259 |
| abstract_inverted_index.95.8)91.9 | 297 |
| abstract_inverted_index.98.1)94.1 | 316 |
| abstract_inverted_index.II–IIIC | 72 |
| abstract_inverted_index.Long-term | 206 |
| abstract_inverted_index.Secondary | 155 |
| abstract_inverted_index.[CI])1.13 | 251 |
| abstract_inverted_index.continued | 143 |
| abstract_inverted_index.endpoints | 156 |
| abstract_inverted_index.follow-up | 186 |
| abstract_inverted_index.including | 218 |
| abstract_inverted_index.invasive, | 376 |
| abstract_inverted_index.long-term | 57, 326 |
| abstract_inverted_index.operable, | 66 |
| abstract_inverted_index.treatment | 146 |
| abstract_inverted_index.underwent | 237 |
| abstract_inverted_index.248iDFSPts | 235 |
| abstract_inverted_index.comparable | 37, 333 |
| abstract_inverted_index.confidence | 249 |
| abstract_inverted_index.consistent | 350 |
| abstract_inverted_index.event-free | 162, 254, 273, 292, 311 |
| abstract_inverted_index.healthcare | 379 |
| abstract_inverted_index.n239234Pts | 239 |
| abstract_inverted_index.n252248Pts | 262, 281, 300 |
| abstract_inverted_index.1.97)4-year | 253 |
| abstract_inverted_index.1.98)4-year | 272 |
| abstract_inverted_index.2.24)4-year | 291 |
| abstract_inverted_index.2.72)4-year | 310 |
| abstract_inverted_index.95.4)OSPts, | 299 |
| abstract_inverted_index.alternative | 381 |
| abstract_inverted_index.convenient, | 374 |
| abstract_inverted_index.established | 369 |
| abstract_inverted_index.intravenous | 31 |
| abstract_inverted_index.neoadjuvant | 49, 85 |
| abstract_inverted_index.ventricular | 76 |
| abstract_inverted_index.92.7)EFSPts, | 261 |
| abstract_inverted_index.chemotherapy | 86 |
| abstract_inverted_index.disease-free | 159 |
| abstract_inverted_index.inflammatory | 70 |
| abstract_inverted_index.maintenance) | 106 |
| abstract_inverted_index.non-inferior | 29 |
| abstract_inverted_index.pathological | 39 |
| abstract_inverted_index.(NCT03493854; | 7 |
| abstract_inverted_index.90.9)DRFIPts, | 280 |
| abstract_inverted_index.HER2-positive | 52, 65, 390 |
| abstract_inverted_index.HER2-targeted | 145 |
| abstract_inverted_index.chemotherapy. | 356 |
| abstract_inverted_index.investigator) | 95 |
| abstract_inverted_index.randomisation | 140 |
| abstract_inverted_index.concentrations | 27 |
| abstract_inverted_index.randomisation, | 150 |
| abstract_inverted_index.observed.Table: | 223 |
| abstract_inverted_index.recurrence-free | 166 |
| abstract_inverted_index.(11.1)Unstratified | 245 |
| abstract_inverted_index.professional-preferred | 380 |
| cited_by_percentile_year | |
| countries_distinct_count | 12 |
| institutions_distinct_count | 15 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8299999833106995 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.13998414 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |